Epicore BioNetworks IncTSXV: EBN

Epicore Stock Option Grants

· Issued by Epicore BioNetworks Inc via CNW

CALGARY, Feb. 5 /CNW/ - Epicore BioNetworks Inc. announces that it has granted stock options to directors of the company. The number of options granted is 150,000, which is equivalent to 0.2% of Epicore's issued common stock. Under the terms of the Epicore Stock Option Plan, which was recently approved by shareholders at the Company's Annual General and Special Meetings of Shareholders, options may be issued from time to time in any amount up to a maximum of 4,702,246. The options currently being issued to directors have an exercise price of Cdn $0.145 and expire in five years. The grant to directors follows Company board compensation policy.

Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity. Epicore is a major supplier to the shrimp aquaculture industry.

Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the Canadian Venture Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.)

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.

Epicore BioNetworks Inc on 6ix

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases